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The membrane bound acetylcholine r ceptor f om Torpedo marmorata was photolabeled by the noncompetitive channel 
blocker [~H]chlorpromazine u der equilibrium conditions in the presence ofthe agonist carbamoylcholine. The radioactiv- 
ity incorporated into the AChR subunits was reduced by addition of phencyclidine, a specific ligand for the high-affinity 
site for noncompetitive blockers. The ~t-subunit was purified and digested with trypsin and/or CNBr and the resulting 
fragments fractionated by HPLC. Sequence analysis resulted in the identification ofSer-248 as a major residue labeled 
by pH]chlorpromazine  a phencyclidine-sensitive manner. This residue is located in the hydrophobic and putative trans- 
membrane segment M2 of the ~t-subunit, a region homologous to that containing the chlorpromazine-labeled S r-262 
in the Nchain [1] and the Ser-254 and Leu-257 in the//-chain [2]. Extended sequence analysis of the hydrophobic segment 
M 1 further showed that no labeling.occurred in this region. 
Acetylcholine r ceptor; Ion channel; Noncompetitive blocker 
1. INTRODUCTION 
The nicot in ic  acetylcholine receptor (AChR) 
f rom vertebrate muscle and fish electric organ is a 
heterologous pentamer (ot2BTt~) which carries the 
acetylcholine-binding sites and contains the cation- 
selective channel forming elements [3,4]. The non- 
competitive blockers (NCBs) are compounds that 
block the permeability response by interfering 
directly and/or  indirectly with the functioning of  
the ion channel [5]. Under equilibrium conditions, 
NCBs reversibly interact with a few categories of  
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sites present on the membrane-bound AChR.  The 
most prominent one is a high-affinity site that 
binds histrionicotoxin and phencyclidine, is 
distinct from, but allosterically coupled to, the 
acetylcholine-binding sites and is present as a 
single copy per AChR oligomer [6,7]. Covalent 
labeling of  this high-affinity NCB site has been 
achieved by using a variety of  NCBs under 
equilibrium conditions [6,8-11]. Depending on the 
ligand and on the species of  Torpedo used, the tr-, 
/5- and/or  ~-chains are selectively labeled, leading 
to the proposal that this unique allosteric site is 
common to all subunits and located in the axis of  
quasi-symmetry of the AChR protein [6,12]. 
Under equilibrium conditions and in the 
presence of  agonist, [3H]chlorpromazine (CPZ) 
bound to its high-affinity site [6,8] selectively 
photolabels all four chains of  Torpedo marmorata 
AChR.  The residues labeled under these conditions 
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belong to the hydrophobic segment M2 of the fl- 
and 8-chains (residues ~?-Ser-254 and fl-Leu-257, 8- 
Ser-262) [1,2]. Also, 8-Ser-262 [13] and 
homologous residues of the or- and g-chains [12] 
are labeled by the NCB [3H]triphenylmethyl- 
phosphonium.  These data thus support the pro- 
posal that the unique high-aff inity NCB site is 
delimited by homologous regions of the five 
subunits,  which include segment M2, where all the 
labeled residues identified so far are located. 
Karl in et al. [14] have mentioned ata (still un- 
published) according to which labeling of T. 
californica or-chain by the NCB [3H]quinacrine 
azide would be located ' in a cyanogen bromide 
fragment containing the segment M 1'. Since the cr- 
subunits already carry the ACh-binding sites, the 
possibil ity exists that their contr ibut ion to the 
high-aff inity site for NCB differs from that of the 
other subunits. In this report, we analyze the label- 
ing of the or-chain by [3H]CPZ and, in particular, 
look for the possible occurrence of labeled residues 
in segment M1. 
2. MATERIALS  AND METHODS 
2.1. Materials 
Phencyclidine was a gift from A. Jaganathen (Universit6 
Louis Pasteur, Strasbourg, France). [3H]CPZ (20-25 
Ci/mmol; 1 Ci = 37 GBq) was purchased from New England 
Nuclear; carbamoylcholine chloride and unlabeled CPZ from 
Sigma; dimethyl sulfide from Fluka; L-l-tosylamido-2-phenyl- 
ethyl chloromethyl ketone (TPCK)-treated trypsin from Merck 
(Darmstadt); and cyanogen bromide from Eastman-Kodak. 
Live T. marmorata were provided by the Station Biologique 
d'Arcachon (France). 
2.2. Covalent labeling of the AChR by [~H]CPZ 
Large batches (200 nmol of a-toxin-binding sites) of purified 
[15] and alkali-treated [16] AChR-rich membrane fragments 
were labeled according to Giraudat et al. [2] with [3H]CPZ 
[2-3 Ci/mmol (preparation 1)or 12-14 Ci/mmol (preparation 
2)1. 
The purification of the labeled a-subunit, subsequent carbox- 
ymethylation, and acetone precipitation were performed as 
previously described [2]. 
The specific radioactivity ofthe purified a-chain did not dif- 
fer significantly from that just after irradiation (typically 
1700 dpm//zg of a-chain vs 650 dpm//~g for the phencyclidine- 
protected batch in preparation 1,and 12200 dpm//~g ofa-chain 
vs 8200 dpm//zg for the phencyclidine-protected batch in 
preparation 2). 
2.3. Trypsin cleavage 
The purified, carboxymethylated a-chain (preparation 1)was 
resuspended (2 mg of protein/ml) in 2 M urea/0.1 mM 
CAC12/50 mM NH4COa, pH 8.2. Trypsin was added to a 1:20 
(w/w) enzyme/substrate ratio. After a 3-h incubation at 37°C, 
the same amount of enzyme was added and incubation prolong- 
ed overnight. 
2.4. CNBr cleavage 
The dry sample was resuspended (0.5-1 mg of protein/ml) in 
5.7 N HCI and incubated for 2 h at room temperature in the 
presence of0.5 M dimethyl sulfide to reduce methionine sulfox- 
ides [17]. The reaction mixture was then lyophilized. The sam- 
ple was redissolved (0.5-1 mg of protein/ml) in 7007o 
heptafluorobutyric acid (preparation 1) or formic acid 
(preparation 2), CNBr was added to an estimated 2000-fold 
molar excess over methionine residues, and the mixture in- 
cubated for 24 h at room temperature under nitrogen in the 
dark. 
2.5. High-pressure liquid chromatography 
The HPLC system used was as described [1]. Peptides were 
chromatographed on a Nucleosil C4 (1000 .~-7/~m) reverse- 
phase column (4.6 x 250 mm) (Soci&6 Fran~aise Chromato 
Colonne), or on a/~Bondapack C18 (10/zm) reverse-phase col- 
umn (3.9 × 300 mm) (Waters). 
2.6. Sequence analyses 
Automated Edman degradation was carried out in a 
Beckman 890 C spinning cup sequenator with 0.1 M quadrol in 
the presence of polybrene as described [2,18]. The sequenator 
output was dissolved in 2007o acetonitrile and aliquots used for 
radioactivity measurements and for identification and quan- 
tification of phenylthiohydantoin-amino acids by HPLC [18] 
on a Microbore column with a solvent system similar to that 
used with the Applied Biosystems 120A PTH analyzer. A few 
degradations were carried out with an Applied Biosystems 470A 
sequencer, with on-line PTH-amino acid analysis in the 120A 
analyzer using the standard programs provided by the supplier. 
3. RESULTS 
3.1. Labeling o f  the ol-subunit by ~H]CPZ 
Large batches of AChR-r ich membrane 
fragments (200 nmol of ~r-toxin-binding sites) were 
photolabeled by [3H]CPZ under equi l ibr ium con- 
ditions in the presence of 1 mM carbamoylchol ine. 
Analytical  polyacrylamide gel electrophoresis of 
[3H]CPZ-labeled membranes confirmed that, as 
shown previously, all AChR chains were labeled 
[6]. In the presence of 200/zM phencyclidine, a 
specific l igand for the high-affinity NCB-binding 
site, the incorporat ion of [3H]CPZ into all receptor 
chains was decreased. 
The AChR cr-subunits derived from membranes 
labeled in the absence, or presence, of phen- 
cyclidine were purified by preparative polyacryl- 
amide gel electrophoresis, with no detectable loss 
of covalently bound [3H]CPZ (see section 2). 
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Analyt ica l  po lyacry lamide gel electrophoresis of  
the puri f ied mater ia l  indicated that approx.  2070 of  
the a-subuni ts  were labeled by [3H]CPZ in a 
phencycl idine-sensit ive manner.  
3.2. Analysis of  ot-subunit ryptic fragments 
Pur i f ied o~-subunit (preparat ion 1) was cleaved 
with trypsin, and the digest f ract ionated by rp 
HPLC (see legend to fig. 1A). Approx .  15070 of  the 
injected radioact iv i ty was associated with unbound 
mater ia l  (data not shown): the amount  of  radioac-  
t ivity in this fract ion was not lower in the 
phencycl id ine-protected sample. This material  was 
not further analyzed. 
Al l  the phencycl idine-sensit ive labeling was 
associated with the broad A23o peak shown in 
f ig . lA ,  which contained 65070 of  the injected 
radioact iv i ty (80070 decrease in the protected sam- 
ple). When this mater ia l  (pool  T1 in f ig . lA )  was 
subjected to automated sequence analysis, three 
amino-terminal  sequences could be identif ied 
(table 1) using the known pr imary structure of  T. 
marmorata -subuni t  m19). The major  one cor- 
responded to a tryptic f ragment extending from 
Ile-210 (no. 1, cleavage at Arg-209), and the region 
sequenced included the entire hydrophobic  seg- 
ment M1 (Pro-211-Thr-237)  (fig.2). The other two 
sequences corresponded to over lapping fragments 
extending f rom Ser-388 (no.2, cleavage at Lys-387) 
and Tyr-401 (no.3, cleavage at Lys-400) which 
derived from the carboxyl - terminal  port ion of  the 
~-subunit .  
A t  each cycle, on the recordings f rom the PTH 
analyzer,  a certain number of  variable background 
peaks were present, which could not be ascribed to 
any specific sequence or mixture of  sequences aris- 
ing f rom trypt ic cleavage at the three posit ions 
ment ioned above. But neither the sequences of  
M2, beginning after Lys-242, nor that of  M3, after 
Lys-276, could be detected. As several sequences 
were present and overlap problems increase with 
the number  of  cycles, the course of  the Edman 
degradat ion could no longer be fol lowed at the 
PTH-amino  acid level after about 28 cycles. 
Results of  radioact iv i ty measurements for this 
degradat ion are given in table 1. A small increase 
over background release was detected at cycle 6 
which, however, by correcting for the repetit ive 
yield (88070) calculated f rom the PTH data,  would 
account for only (1213-500)/(0.88) 6 = 1535 dpm 
loaded.  This small amount  of  radioact iv i ty could a 
pr ior i  reflect either a minor site of  [3H]CPZ incor- 
porat ion  on one of  the identif ied peptides or the 
presence of  [3H]CPZ on a minor  peptide that 
escaped identi f icat ion at the PTH-amino  acid 
level. 
Fig. 1. Reverse-phase HPLC of o~-subunit fragments. (A) Purified labeled o~-subunit (50 nmol of preparation 1)was incubated with 
trypsin (see section 2). The dried digest was dissolved in formic acid, then diluted with 9 vols of 25 % solvent A (0.1°70 trifluoroacetic 
acid in H20)/75070 solvent B (0.1070 trifluoroacetic a id, 90070 n-propanol) and filtered through a Sep-pak Cla cartridge (Waters) 
equilibrated at75% solvent B. The flowthrough was diluted to 40070 solvent B by addition of solvent A, and one third loaded onto 
the column by multiple injections under isocratic onditions (data not shown) at 40070 solvent B. The column was then eluted at 
0.5 ml/min with the gradient of solvent B indicated, and the eluate was monitored at 230 nm (solid trace). Aliquots of the fractions 
collected at 2-min intervals were subjected to liquid scintillation counting (o). Parallel treatment ofo~-subunit from the phencyclidine- 
protected sample produced a similar .4230 profile (not shown) and the radioactivity profile shown here (•). The horizontal bar indicates 
the material pooled (pool T1) for subsequent characterization. (B) Purified labeled a-chain (20 nmol of preparation 2)was treated 
with CNBr in 70070 formic acid (see section 2). The incubation mixture was then dried, and hydrophilic peptides were extracted in4 M 
guanidinium chloride, 6070 n-propanol, 3070 acetonitrile, 0.107o trifluoroacetic a id. The remaining insoluble material (9007o f original 
radioactivity) was dissolved in pure formic acid, diluted in 7007o solvent A (10% formic acid in H20)/30070 solvent B (10070 formic acid, 
90% n-propanol). Samples of this material were then loaded onto a Cls/~Bondapack olumn equilibrated at 30070 solvent B. The 
column was eluted at 1 ml/min with the indicated gradient. Eluate was monitored at 280 nm. Even at the highest injected amount, 
no absorption peak was detected. Fractions were collected at 1-min intervals and aliquots of non-protected sample (e) and of equal 
amounts of phencyclidine-protected digest (•) were subjected toliquid scintillation counting. The horizontal bars indicate the material 
pooled (pools BFI and II) for subsequent characterization. (C)Tryptic peptides contained in pool T1 of A (corresponding to27 nmol 
of o~-starting chain) were dried and subcleaved with CNBr in 70% heptafluorobutyric acid. The incubation mixture was then diluted 
with 25070 solvent A (0.13070 heptafluorobutyric acid in H20)/75070 solvent B (0.13°70 heptafluorobutyric acid, 90070 n-propanol), 
filtered through a Sep-pak cartridge and loaded onto the nucleosil C4 column equilibrated at40070 solvent B. With one third of the 
sample, elution of the column produced the A23o (solid line) and radioactivity (o) profiles shown here. Total recovery of injected 
radioactivity was 60°70. The horizontal bar indicates the material pooled (pool T + BH0 for sequence analysis. (D) The unbound 
material in the above chromatography (C) was collected, dried, solubilized in formic acid and loaded on the column equilibrated at
5070 solvent B (0.1070 trifluoroacetic a id, 90070 n-propanol). Only the portion of the A230 (solid line) and radioactivity (o) elution 
profiles containing the peak of radioactive material is shown. Total recovery of injected radioactivity was 75070. The bar indicates the 
material pooled (pool T + BH2) for sequence analysis. 
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At cycles 2, 12 and 27, where proline residues 
were expected in fragment no. 1, the acid cleavage 
reaction was extended from 2 to 7 min to improve 
the Edman degradation yield [20]. Although unex- 
pected, the small increase in radioactivity release 
observed at these cycles (table 1) most probably 
resulted from this prolonged incubation in acid. 
Most interestingly a marked release of radioac- 
tivity was found between cycles 38 and 41 with a 
peak at cycle 39 (table 1). Correction for the 
repetitive yield indicates that this release must have 
represented (a) major site(s) of [3H]CPZ labeling 
of the material loaded. 
Among the three identified sequences, equence 
no.3 starting at Tyr-401 could, at most, extend 
down to the ultimate or-chain residue (Gly-437) and 
thus could not carry the radioactivity detected 
here. Furthermore, since sequence no.2 precedes 
sequence no.3 by 13 residues, the radioactivity 
which reached a peak at cycle 39 could not belong 
to Phe-426, otherwise one would have obtained a
peak also at cycle 39-  13 = 26. The remaining 
candidates thus appear to belong to sequence no. 1 
(Ser-248 and possibly Ile-247 within segment M2). 
3.3. Analysis of o~-subunit cyanogen bromide 
fragments 
Purified a-subunit (preparation 2) was cleaved 
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total digest was submitted to reverse-phase HPLC 
(see legend to fig.lB). The amount of loaded 
material (3 nmol) was too low to permit detection 
of the eluted peptides at 280 nm. Furthermore, the 
presence of 10°70 formic acid in solvent A and B 
precluded etection at 210 nm. Approx. 60070 of 
the recovered radioactivity was eluted between 40 
and 80°/o solvent B (fig.lB). This material was 
divided into pool BFI (F 38-49) and pool BFII (F 
50-65) and subjected to automated Edman 
degradation i  an ABI 470 A sequencer. No pro- 
gram modification was attempted at cycles where 
proline was expected. 
In the first half-dozen cycles, it was clear that 
several peptides were being degraded, but most of 
them could not be identified with certainty. The 
only sequence which could be followed down to cy- 
cle 13 corresponded to the fragment beginning at 
Gin 208 (table 2). No peptide sequence resulting 
from cleavage at the Met-243-Thr-244 bond 
(beginning of the hydrophobic segment M2) could 
be detected at the PTH-amino acid level. Results 
of radioactivity measurements on the sequencer 
output are given in table 2: no significant radioac- 
tivity release was observed. This showed that the 
peak observed at cycle 6 upon sequencing of the 
tryptic fragments (table 1) did not correspond to 
the labeling of Val-215 in segment M1. This amino 
acid was released at cycle 8 and, if it had indeed 
been labeled, the corresponding radioactivity 
should have been approximately 300 dpm over 
background (for details, see footnote), instead of 
the 35 dpm observed. Analysis of pool BFI (not 
shown) did not provide further information. 
3.4. Analysis of  CNBr sub fragments of  the tryptic 
digest 
In order to establish with more confidence the 
identity of the residue(s) found labeled at cycles 
Upon sequencing of tryptic peptides (preparation 1; 
68 dpm/pmol of o~-chain) 439 pmol of Val-215 together with 
713 dpm were released atcycle 6 (table 1). Upon sequencing of 
CNBr fragments (preparation 2; 488 dpm/pmol of oe-chain) 
29 pmol of Val-215 were released atcycle 8 (table 2). After cor- 
rection for the different specific radioactivity of tr-chain 
preparations u ed, radioactivity associated with 29 pmol of 
Val-215 should have been approx. 713 × (29/439) ×(488/68) =
338 dpm 
38-41 of the tryptic fragments equence analysis, 
the tryptic peptides of pool T1 were subcleaved by 
CNBr. 
However, as mentioned above, after treatment 
of the or-chain by CNBr in 70070 formic acid, we 
could not detect any sequence resulting from 
cleavage of the a-Met-243-Thr-244 bond. 
Cleavage of Met-Thr  bonds by CNBr has indeed 
been reported to occur in low yields [21] under 
these conditions (70o70 formic acid). We thus tested 
various solvents in order to achieve cleavage of the 
c~-Met-243-Thr-244 bond. Heptafluorobutyric 
acid and high concentrations of CNBr (see section 
2) proved to be satisfactory [22] and were used here 
(see legend to fig. 1C). 
The digest was loaded on the rp HPLC column 
equilibrated at 40°70 solvent B. Approx. 33°70 of the 
radioactivity recovered from the HPLC column 
was eluted between 45 and 70070 solvent B in 
association with a broad A230 peak (fig.lC). This 
material was pooled (pool T + BH1) for subsequent 
sequence analysis. The unbound material, which 
contained the rest of the radioactivity, was dried 
and reanalyzed using a gradient starting at 5070 sol- 
vent B. Approx. 65°70 of the recovered radioactivi- 
ty was eluted between 30 and 40°70 solvent B 
(fig.lD). This material (pool T+B~I2) was also 
characterized. The unadsorbed radioactive 
material was not analyzed further. 
When pool T+BH1 was submitted to Edman 
degradation i a Beckman 890C sequencer, several 
sequences were present. Their identification was 
facilitated by the previous analysis of the starting 
mixture of tryptic peptides. On the basis of the in- 
crease and the decrease of a few characteristic 
amino acids at selected cycles, six sequences were 
identified (table 3). Two of them (nos 1 and 2) were 
present in the starting mixture, while sequence 3
could not be observed; instead, fragments arising 
from cleavage at Met-404 (no.3 bis), before seg- 
ment M4, and at Met-415, in segment M4 (no.3 
ter), were present. Moreover sequences beginning 
after Met-243 (no.4) and after Met-282 (no.5) were 
also detected (see fig.2). 
An important phencyclidine-sensitive rel ase of 
radioactivity was observed at cycle 5 (fig.3a). Tak- 
ing into account he a-chain specific radioactivity 
(42000dpm/nmol) and an assumed average 
repetitive yield of 88%, this must have correspond- 
ed to at least 235 pmol of labeledpeptide at this cy- 
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Table 1 
Sequence analysis of oe-subunit tryptic fragments in pool TI 
August 1989 
Cycle dpm PTH-amino acids (pmol) Cycle dpm PTH-amino acids (pmol) 
in sequence in sequence 
No.l No.2 No.3 No.1 No.2 No.3 
1 196 1 835 S + Y 472 23 247 V 37 a L 85 V 37 a 
2 550 P 373 D302 V 276 24 302 F 95 L 114 (C) 
3 435 L 1068 E 554 A528 25 290 Y 73 (C) (V) 
4 494 Y 823 E 878 M310 26 329 L 103 V 108 F 21 
5 565 F 548 S + V 244 27 802 P 30 F 27 A13 
6 1213 V 439 S + I 235 28 245 (T) M33 G 18 
7 707 V 790 N 155 (D) 29 258 (D) 
8 709 N 308 A 454 (H) 30 257 (S) 
9 641 V 652 A506 I 197 31 228 G17 
10 572 I 346 E 322 L 243 32 254 E 12 
11 357 I 296 E 461 L 233 33 251 
12 721 P 256 (W) (C) 34 219 
13 492 (C) (K) V 195 35 222 
14 547 L 164 Y 220 F 42 36 215 
15 605 L 216 V 158 M 100 37 288 
16 445 F 108 A 171 L 71 38 478 
17 526 (S) M79 I 116 39 772 
18 413 F 88 V 127 (C) 40 662 
19 551 L 100 I 268 a 1 268 a 41 547 
20 432 (T) (D) I 77 Starting position ~210 ~388 ~401 
21 183 V 79 (R) G 43 Initial amount (pmol) 1032 691 549 
22 160 L 134 I 71 (T) Repetitive yield 88% 90% 88% 
A sample (488000 dpm) of material contained in pool T1 (fig.lA) was analyzed. The PTH-amino acids 
identified at each cycle are designated by the conventional one-letter code. Yields are corrected for background. 
For lack of a reliable calibration standard, PTH-Ser could not be quantified. Residues (a) can be attributed to 
two different fragments at the particular cycle. Residues in parentheses are those expected according to the 
deduced sequence when they could not be identified or when their corresponding PTH peak, although present, 
did not rise above the chosen background. The start position indicates the location of the amino-terminal residue 
in the complete sequence; the initial amount of peptide undergoing degradation and repetitive yields were 







(a) KYVAMVI D.. F... 
i .'."2"I-IIII~ COO H 
~) KSDEESSN.. F... 
388 426 
210 405 
(~)R IPLYFVV... ($bi~) MVI DHILL... 
- -  T , 
(4) M TLSISVL (~)KSDEESSN 
244 248 388 
cle. Th is  value was above  the detect ion  l imit for  
PTH-amino  acids,  there fore  the sequence  cor-  
respond ing  to the  labeled pept ide  must  have been  
among the six ident i f ied  ones.  Since the analysis  o f  
the  t rypt ic  pept ide  mix ture  had  ruled out  sequences  
nos  1, 2, 3 bis and  3 ter,  the labeled res idue was 
e i ther  Ser-287 or  Ser-248. 
Fig.2. Location of sequenced peptides within the t~-subunit 
primary structure. Schematic drawing of the a-subunit. Black 
boxes indicate the four hydrophobic segments (M1-M4), and 
the open box indicates the putative amphipathic helix ~/. 
Identified tryptic (upper part) and CNBr (lower part) peptides 
from a-subunit digests are localized along the sequence of 
Torpedo marmorata ot-subunit. [3H]CPZ-labeled tr-Ser-248 is 
marked with an asterisk. 
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Table 2 
Yields of  PTH-amino acids upon sequence analysis of  pool BFII 
peptides 
Cycle dpm ~r-subunit pmol of  
sequence xtending PTH-amino acid 
from Gln-208 
1 889 Q 60 
2 454 R 50 
3 324 I 90 
4 245 P 25 
5 276 L 25 
6 305 Y 44 
7 314 F 28 
8 350 V 29 
9 268 V 54 
10 276 N 18 
11 232 V 15 
12 220 I 15 





A sample (280000 dpm) of material contained in pool BFII 
(fig.lB) was subjected to automated Edman degradation. 
Details are as given in table 1 
The idea that Ser-248 was the labeled residue is 
supported by its tentative identification atcycle 39 
of the tryptic peptide degradation. It is also sup- 
ported by the consideration that the small radioac- 
tivity increase at cycle 6 of the tryptic peptides 
degradation may have arisen from a small amount 
of tryptic cleavage at the Lys-243-Met-244 bond, 
which would have yielded an amount of peptide 
undetectable at the PTH level, yet degradable in
the sequencer. 
Ile-247 was clearly not found labeled in the 
degradation f the CNBr peptides. The reason why 
radioactivity was already observed, in the tryptic 
peptide degradation, atcycle 38 (which could have 
corresponded to I1e-247), remains unexplained, as 
sequence no.1 does not contain a histidine which 
could have given rise to a certain amount of 
preview [23]. 
No radioactivity was released at cycle 5 upon se- 
quence analysis of material purified in parallel 
from the tr-subunit labeled in the presence of phen- 
cyclidine (fig.3A). Analysis of pool T+ BH2 in- 
dicated a somewhat different relative amount of 
the peptides compared to pool T + BH1 (not shown) 
but radioactivity was also released at cycle 5 
(fig.3B). This result strengthened the idea derived 
from the degradation of pool T +Bm that Ser-248 
is the amino acid labeled by chlorpromazine in the 
ce-subunit. 
Table 3 
Yields of PTH-amino acids upon sequence analysis of pool T + BH1 peptides 
Cycle dpm PTH-amino acids (pmol) in sequence 
No.1 No.4 No.5 No.2 No.3 bis No.3 ter 
1 3234 I 1206 b T + 1 1206 b S + V 727 L 1486 
2 1228 P 464 L 897 F 534 D 174 I 557 b I 557 b 
3 1494 L 544 S 994 a V 160 E 280 D 67 (C) 
4 834 Y 421 I 855 b 1 855 b E 576 (H) I 855 b 
5 11856 F 504 S 1455 a'b S 1455 a'b S 1455 a'b I 1177 b I 1177 b
6 3956 V 513 b V 513 b S 1024 a'b S 1024 a'b L 566 G 382 
7 1420 V 396 L 719 b I 476 N 101 L 719 b (T) 
8 1574 N 158 L 650 I 471 A 338 V 702 
9 1086 V 770 b S 360 ~'b V 770 A 385 V 770 S 360 ~'b 
10 738 I 113 L 141 (E) F 150 V 416 
11 704 I 304 (T) E 188 F 380 
Starting position ~210 ot244 oe283 ce388 oe405 a416 
a These amounts of  identified PTH-Ser are given on an arbitrary scale (see table 1), only 
to illustrate the relative amounts released at various cycles 
A sample (331000 dpm) of material contained in pool T + Bm (fig. 1C) was subjected to 
automated Edman degradation. Details are as given in table 1. Due to the high number 
of  cycles where the same residue (b) can be attributed to different peptides, no average 
repetitive yield could be calculated 
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Fig.3. Radioactivity released upon sequence analysis of CNBr 
subfragments from [3H]CPZ-labeled a-chain. (A) A sample 
(331000 dpm) of pool T+Bm was subjected to automated 
sequence analysis. The amount of radioactivity present in the 
PTH fraction at each cycle is shown (o). Radioactivity released 
upon sequencing of similar material (19000 dpm, 
corresponding to 4-5 times less protein as judged from PTH- 
amino acids quantification) derived from phencyclidine- 
protected o~-chain is also shown (o). For comparison, 
radioactivity released upon sequencing of material 
(488000 dpm) in pool T1 is shown at the same scale (A). All 
these samples were derived from preparation 1 of oe-chain. (B) 
Same as in (A) for a sample (106000 dpm) of pool T + BH2 (e), 
and for the similar phencyclidine-protected material 
(10500 dpm) (o). 
4. DISCUSSION 
The high-affinity site for NCB [24,25] is present 
as a single copy per AChR and appears delimited 
by all five subunits [7,26]. The degree of symmetry 
of the AChR molecule inferred from mor- 
phological and primary structure data, can thus be 
experimentally tested at this level. Furthermore, 
electrophysiological (review in [27-29]) as well as 
biochemical (review in [6,30]) evidence supports 
the view that the high-affinity NCB site is located 
within the ion channel. Photoactivatable NCBs are 
thus useful tools for direct identification of poten- 
tial channel-forming elements within each of the 
AChR subunits [1,2,12,13]. 
Due to the marked hydrophobic character of the 
cr-subunit fragments studied here, their 
biochemical characterization faced strong 
technical imitations (discussed in [2]), also en- 
countered by others [12] with several AChR 
subunits. It turned out even more difficult than for 
~- and cLchains [1,2] to separate from one another 
the various fragments containing one or multiple 
hydrophobic segments, possibly owing to aggrega- 
tion. Sequence analysis of partially purified tryptic 
peptides and CNBr subfragments enabled us, 
however, to propose Ser-248 as a major site of 
phencyclidine-sensitive incorporation of [3H]CPZ 
into the a-subunit [additional labeling of a-Ser-287 
cannot be ruled out at this stage (see section 3)]. 
Residue cr-Ser-248 is found in segment M2 at a 
position homologous to ~-Ser-254 and cLSer-262, 
which are also specifically labeled by [3H]CPZ 
[1,2]. The present finding thus brings additional 
evidence that homologous regions from each 
subunit contribute to the single phencyclidine- 
protectable CPZ-binding site. Accordingly, the 
transmembrane segment M2 of each subunit would 
lie close to the central axis of symmetry of the 
AChR molecule and would be oriented so as to 
render the above residues accessible to CPZ when 
bound to its high-affinity site [2]. This conclusion 
can also be derived from the observation that 
[3H]triphenylmethylphosphonium labels segment 
M2 of the ol-,/5- and t~-chains [12]. 
Our extended sequence analysis on the tryptic 
pool T1 and the CNBr fragments of pool BvII con- 
clusively showed the absence of [3H]CPZ incor- 
poration on any of the residues composing 
segment M1. The report by Karlin et al. [14] that 
"the site on c~ which is specifically labeled by 
[3H]quinacrine azide is within a CNBr fragment 
containing MI"  thus appears challenging. Indeed, 
[3H]quinacrine azide specific labeling is inhibited 
by histrionicotoxin and thus is expected to take 
place at the level of a site overlapping, if not iden- 
tical, to the high-affinity NCB site studied here 
[31]. In the absence of published experimental 
data, the possibility that the residue(s) labeled by 
[3H]quinacrine azide belong to segment M2 rather 
than to M1 cannot be excluded since, in our hands, 
the Met-243-Thr-244 bond (preceding segment 
M2) resisted CNBr treatment of the a-subunit 
under standard conditions, whereas the 
Met-207-Glu-208 bond (preceding M1) was nor- 
really cleaved. 
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The results of covalent labeling with CPZ and 
tr iphenylmethylphosphonium provide convergent 
evidence that segments M2 are potential com- 
ponents of the ion translocation device. Consistent 
with this view, site-directed mutagenesis ex- 
periments have shown, following the original 
observation of Giraudat et al. [I] and Oberthiir et 
al. [13], that a region of the ~-subunit comprising 
segment M2 and the port ion between segments M2 
and M3 contribute to the regulation of ion 
transport  [32]. More recent works from the same 
groups have shown that clusters of charged 
residues neighbouring both ends of segment M2 of 
the a-,  fl-, 7"- and d-subunits are major  deter- 
minants  of the rate of ion transport [33]. Further- 
more, mutat ion of the serines homologous to 
~-Ser-262 [1] into alanines on several subunits of 
the AChR from mouse BC3Ht cells [34] caused a 
decrease in outward K ÷ currents and reduced 
residence time of the NCB QX222 thought o bind 
within the open channel [28]. Also, synthetic pep- 
tides corresponding to segment M2, but not to seg- 
ment M1 of ~-subunit from Torpedo AChR,  form 
discrete ion channels in artificial bilayers [35]. 
The present data on the cr-subunit pointing at 
Ser-248 as a major  residue labeled by [3H]CPZ 
thus bring addit ional support to the contr ibut ion 
of segment M2 to the structure of the ion channel 
[1,2,12,33]. 
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